Payment overview · 2025
General Payments
$609.83
30 reported records · 15 companies
Healthcare provider profile · identity verified
Brant Holtzmeier, D.O
Allopathic & Osteopathic Physicians|Family Medicine · WESTLAKE, OH · NPI 1760460356
Verified facts
What the public records show
CMS Open Payments records show Brant Holtzmeier, D.O received $609.83 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $82.16 | 13.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $73.21 | 12.0% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $71.79 | 11.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $53.19 | 8.7% | 3 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.97 | 6.9% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $41.21 | 6.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.38 | 6.6% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $37.01 | 6.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $31.78 | 5.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.53 | 4.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.43 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.25 | 3.8% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $20.50 | 3.4% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $19.41 | 3.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.01 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $609.83 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $73.21 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $71.79 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $53.19 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.52 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $41.21 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $31.78 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $28.53 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $20.50 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $17.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 540 | 153 |
| Amlodipine Besylate | Amlodipine Besylate | 340 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 335 | 82 |
| Losartan Potassium | Losartan Potassium | 283 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 75 |
| Lisinopril | Lisinopril | 247 | 73 |
| Omeprazole | Omeprazole | 192 | 56 |
| Simvastatin | Simvastatin | 181 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 150 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 150 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 38 |
| Eliquis | Apixaban | 140 | 26 |
| Gabapentin | Gabapentin | 130 | 36 |
| Pioglitazone Hcl | Pioglitazone Hcl | 129 | 37 |
| Allopurinol | Allopurinol | 112 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 32 |
| Metformin Hcl | Metformin Hcl | 99 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 93 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 28 |
| Furosemide | Furosemide | 90 | 29 |
| Alendronate Sodium | Alendronate Sodium | 82 | 24 |
| Tramadol Hcl | Tramadol Hcl | 82 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 81 | 63 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 80 | 22 |
| Atenolol | Atenolol | 78 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 25 |
| Synthroid | Levothyroxine Sodium | 68 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 18 |
| Montelukast Sodium | Montelukast Sodium | 67 | 23 |
| Jardiance | Empagliflozin | 63 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 17 |
| Potassium Chloride | Potassium Chloride | 60 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Meloxicam | Meloxicam | 58 | 32 |
| Azithromycin | Azithromycin | 55 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 24 |
| Januvia | Sitagliptin Phosphate | 47 | 15 |
| Ozempic | Semaglutide | 47 | suppressed |
| Carvedilol | Carvedilol | 46 | 13 |
| Prednisone | Prednisone | 46 | 26 |
| Trazodone Hcl | Trazodone Hcl | 46 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Celecoxib | Celecoxib | 39 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 19 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Bupropion Xl | Bupropion Hcl | 35 | suppressed |
| Glipizide | Glipizide | 34 | suppressed |
| Glipizide Er | Glipizide | 33 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Valsartan | Valsartan | 31 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 21 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 21 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Lorazepam | Lorazepam | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Glyburide | Glyburide | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 13 |
| Topiramate | Topiramate | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $609.83 · 30 records | ABBVIE INC. | AUSTEDO XR, Auvelity, BEYFORTUS, CAMZYOS, Dexcom G6 Transmitter, ELIQUIS, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 2, GVOKE HYPOPEN, Heplisav-B, Kerendia, Korlym, OFEV, QULIPTA, RECORLEV, REXULTI, UBRELVY, VRAYLAR, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error